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Safetya b s t r a c t
The use of whole-food (grain meal contained in feed) animal-feeding studies to support the safety
assessment of genetically modiﬁed crops has been contentious. This may be, in part, a consequence
of poorly agreed upon study objectives. Whole-food animal-feeding studies have been postulated to
be useful in detecting both expected and unexpected effects on the composition of genetically
modiﬁed crops. While the justiﬁcation of animal feeding studies to detect unexpected effects may
be inadequately supported, there may be better justiﬁcation to conduct such studies in speciﬁc cases
to investigate the consequences of expected compositional effects including expression of transgenic
proteins. Such studies may be justiﬁed when (1) safety cannot reasonably be predicted from other
evidence, (2) reasonable hypothesis for adverse effects are postulated, (3) the compositional component
in question cannot be isolated or enriched in an active form for inclusion in animal feeding studies,
and (4) reasonable multiples of exposure can be accomplished relative to human diets. The study
design for whole-food animal-feeding studies should be hypotheses-driven, and the types of data
collected should be consistent with adverse effects that are known to occur from dietary components
of biological origin.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
1.1. Objective of feeding studies
The use of whole-food (grain meal contained in feed)
animal-feeding studies to inform the safety assessment for
genetically modiﬁed (GM) crops is quite controversial. Part of
this controversy stems from differences in perspectives concerning
the objectives of such studies. These perspectives may include:
(1) that whole-food animal-feeding studies are of no or little
value in the safety assessment of GM crops no matter what
their purported purpose; (2) that these studies are useful for
detecting unexpected compositional changes that might cause
adverse effects in animals; (3) that such studies are useful in
evaluating expected compositional changes that may cause
adverse effects; (4) and/or that these studies are useful in a
subset of cases where large multiples of exposure for transgene
products (e.g. proteins) are possible in animal feed comparedwith human food (EFSA, 2008; Knudsen and Poulsen, 2007;
Kok et al., 2008).
1.2. Unexpected effects
The issue of unexpected compositional changes having adverse
health effects has been discussed extensively in the literature, and
from a scientiﬁc, evidence-based perspective, it appears that trans-
genesis is less likely to cause such effects compared with tradi-
tional breeding (Herman et al., 2009; Herman and Price, 2013;
Ricroch, 2013). This calls into question, not only the general use
of compositional equivalence studies to uniquely inform the safety
assessment of GM crops, but by extension, the use of whole-food
animal-feeding studies for the same purpose.
1.3. Expected effects
The issue of whether whole-food animal feeding studies
might be useful in certain circumstances to evaluate potential
adverse effects of intended or expected compositional changes,
including expression of novel food proteins, has been less
discussed. Here we brieﬂy outline the potential merits of such
studies in evaluating the safety of GM crops and discuss how
such studies might address reasonable hypotheses concerning
adverse effects.
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2.1. Background
GM crops are engineered to contain genes inserted using re-
combinant DNA technology. Most often these genes produce novel
proteins in terms of their previous history as constituents in food
crops. Common examples include expression of enzymes that de-
grade certain herbicides or are homologues of endogenous plant
enzymes that are insensitive to certain herbicides (rendering
plants tolerant to these herbicides), and insecticidal toxins (provid-
ing insect pest protection). Transgenes may also produce transcrip-
tion factors (also proteins) that modulate other plant genes, or
RNAs that can also modulate plant genes or insect-pest genes, with
the latter enabling traits that can be designed to intoxicate pest in-
sects (Parrott et al., 2010). If novel gene products are expressed in
food crops, then many believe that the safety of these products
should be evaluated for human safety.
2.2. Exposure
Human health risk is a function of hazard (intrinsic toxicity) and
exposure (e.g. how much of the transgene product ends up in the
food we eat) (Kok et al., 2008). For commercial GM crops, the trans-
gene products have thus far been found to be inactivated during
food processing and/or cooking, so exposure to an active transgene
product is negligible (Hammond and Jez, 2011). Proteins are most
commonly able to exert their function based on their speciﬁc fold-
ing pattern or three-dimensional conformation. Elevated tempera-
tures typically cause an irreversible denaturation (unfolding) of the
protein accompanied by loss of function (Privalle et al., 2011). In
such cases, exposure to an active protein is absent in food render-
ing the denatured protein a nutrient source that is digested into
the amino acid subunits required by animals to survive (Delaney
et al., 2008).
2.3. Hazard
If exposure to an active transgene product is reasonably ex-
pected in food, the hazard should be evaluated (likewise if no haz-
ard is identiﬁed, exposure is irrelevant). The potential for adverse
effects can be informed by a number of factors. These include:
(1) history of safe consumption; (2) similarity to other dietary con-
stituents with a history of safe consumption; (3) mode or mecha-
nism of action; and (4) relationship to proteins with known
adverse effects (e.g. toxins or allergens) (Delaney et al., 2008). If
these factors are insufﬁcient to establish low risk, then empirical
toxicity studies may be warranted to investigate the human-health
hazard. In cases where the active transgene product can be isolated
or signiﬁcantly enriched, controlled-dose animal feeding studies
with the puriﬁed or enriched transgene product provide the most
scientiﬁcally robust approach (Kok et al., 2008). In such cases,
the transgene product in the puriﬁed preparation must be shown
to be biochemically and functionally equivalent to that produced
by the GM crop (Raybould et al., 2012). Use of high-dose animal
toxicity studies with puriﬁed compounds has an established his-
tory of value in the safety evaluation (Delaney et al., 2008). The
ability to dose at many multiples of the expected exposure levels
present in real-life scenarios provides a robust evaluation of
hazard.
2.4. Risk
Where: (1) exposure to the functional gene product is reason-
ably expected; (2) there are reasonable uncertainties as to the haz-ard of the gene product based on other knowledge; and (3) the
transgene product cannot be puriﬁed or enriched in an active form
equivalent to what is produced in the GM crop (Madduri et al.,
2012), then the use of whole-food animal-feeding studies might
be considered to inform the human-health risk assessment, if cer-
tain criteria can be met; (1) reasonably high multiples of exposure
can be obtained for the active transgene product compared with
expected human exposure, and (2) matched isogenic non-trans-
genic controls can be produced (under equivalent environmental
conditions) (Knudsen and Poulsen, 2007).
2.5. Multiples of exposure
As an example, for soybean in the European Union, expected
dietary inclusion in high-exposure populations is <3% soy in the
diet (WHO GEMS Cluster Diet F; http://www.who.int/foodsafety/
chem/gems/en/index1.html). Since inclusion of >30% soy in animal
feed is possible without adverse effects in certain species (e.g. rats
and broiler chickens), a >10-fold multiple of exposure is possible
(Herman et al., 2011a). If a transgene product can survive in an ac-
tive form in processed soy (which must be heated to inactivate
endogenous protein antinutrients), then whole-food animal feed-
ing studies may provide some value in the human-health risk
assessment due to increased inclusion of the commodity in animal
feed compared with human diets. A second example of where
whole-food animal-feeding studies might be useful is in situations
where a transgene product is largely inactivated by processing (e.g.
in processed or cooked corn-based food products), but in which
some active protein might remain. Since raw corn meal can be
fed to some animal species at high levels in the diet, and human
consumption of raw corn grain is negligible, very large multiples
(>100-fold) of the active transgene product may be fed in whole-
food animal-feeding studies compared with human exposure,
again potentially providing value in the human-health risk assess-
ment (EFSA, 2008; Herman et al., 2011b).
2.6. Justiﬁcation
Whole-food animal-feeding studies for evaluating the safety of
transgene products (e.g. proteins) have been criticized for being
too insensitive to detect adverse effects. However, some proteins
are quite potent as oral toxicants (e.g. as little as 100 ng of orally
ingested botulism toxin can be fatal in humans) (Schantz and John-
son, 1992), and other food proteins are quite toxic at natural levels
in food crops (e.g. raw kidney beans can kill rats due to the pres-
ence of kidney bean lectin, while humans get sick if they consume
under-cooked kidney beans) (de Oliveira et al., 1988). From a prac-
tical standpoint, if reasonable multiples of exposure are achieved,
then the concentration of the transgene product in the study is
appropriate for evaluating safety since expected exposure is
greatly exceeded (Knudsen and Poulsen, 2007).
It is noteworthy that, for experimental purposes, the kidney
bean lectin was actually expressed in transgenic rice at 0.067%
(30 mg lectin in 45 g of rice, which is 3 to 15-fold lower than the
concentration reported in various kidney bean cultivars), and when
this rice was fed to rats at an incorporation rate of 60% in the diet
for 90 days, statistically signiﬁcant increases in the weights of the
small intestine, stomach, and pancreas were observed compared
with non-transgenic rice (expected adverse effects of kidney bean
lectin) (Knudsen and Poulsen, 2007; Muzquiz et al., 1999; Poulsen
et al., 2007). This provides an example of where a whole-food ani-
mal-feeding study can detect adverse effects even when the con-
centration of the transgene-product is considerably below the
level that occurs naturally in a food crop.
Another common assertion is that no feeding study has raised a
safety issue for a GM crop intended for human consumption, so
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study of any kind has raised a substantiated health issue for a
GM crop intended for consumption), it would follow that no safety
studies are useful (which some have proposed, but many reject).
2.7. Context
Novel gene products can and have been introduced into food
crops through non-GM breeding methods. Cross-breeding with
rare alleles and wild relatives, as well as intentional mutagenesis,
is qualitatively similar to transgenesis (with the exception that
changes due to traditional breeding are often multiple, unknown,
and uncharacterized) and our experience with assessing the safety
of traditionally bred crops should be considered in our approach to
assessing the safety of GM crops (Herman and Price, 2013).3. Expected changes in crop composition
3.1. Background
In addition to expressing gene products, GM crops may be engi-
neered to have a modiﬁed composition or otherwise be expected to
have an altered crop composition (Kok et al., 2008). This may be
through modulation of endogenous plant biochemical pathways
via transcription factors, RNAi, or expression of enzymes that cat-
alyze reactions within plants (Parrott et al., 2010). If the composi-
tion of the crop is expected to be altered, hypothesis-driven
compositional analysis of the relevant crop tissues (e.g. grain) is
an obvious approach to understanding the nature and magnitude
of the changes (Herman and Price, 2013). After characterizing these
compositional changes, their biological relevance should be evalu-
ated. It is noteworthy that whole-food animal-feeding studies may
be needed to evaluate the claimed beneﬁcial effects of GM crops
designed for enhanced nutrition, but here we focus on safety
assessment. To assess safety, any changes to crop composition
are ﬁrst evaluated compared with the breadth of composition for
varieties of the same crop to determine if they represent a novel
change or simply a different method of achieving a similar compo-
sition already present in that crop (and having a history of safe
use). A next step might be to compare the novel composition with
other crops or foods used for similar purposes (e.g. does the oil
from a GM crop resemble the oil from an alternative crop – canola
oil vs. olive oil). Finally, the biological relevance of any composi-
tional change should be evaluated within the context of human
diets (Herman et al., 2010).
3.2. Reasonable uncertainty
If the above evaluation leaves reasonable doubt as to the safety
of the GM crop with altered composition, whole-food animal-feed-
ing studies may be appropriate to evaluate potential adverse
health effects. For example, broilers are extremely sensitive to
nutritional imbalances due to their rapid growth (approximately
60-fold weight gain in 6 weeks) (Herman et al., 2011a,b). However,
if an individual composition component is in question regarding its
safety, and if this component can be isolated in a form equivalent
to what is present in the crop, then high-dose animal feeding stud-
ies with the component in question will likely be more informative
compared with whole-food testing.
3.3. Justiﬁcation
Whole-food animal-feeding studies for evaluating safety have
been criticized for being too insensitive to detect adverse effects
of altered composition, but it seems reasonable to conclude that,if whole-food animal-feeding studies can be designed to detect
the beneﬁts of nutritionally enhanced GM crops, then they could
also be designed to detect potential adverse effects of altered crop
composition.3.4. Context
It should be noted that compositional changes have been ef-
fected in crop varieties through conventional breeding, and the
safety of such crops should be considered when evaluating GM
crops. Speciﬁcally, the novelty and potential risk of a trait should
govern the appropriate steps in assessing risk, rather than the
method of achieving the ﬁnal product (Kok et al., 2008).4. Design of feeding studies
By far the most common whole-food animal-feeding studies
used for evaluating the safety of GM crops are the 90-day rat study
and the 42-day broiler chicken study. The 90-day rat study has
been adapted from chemical toxicology approaches without signif-
icant modiﬁcation (EFSA, 2008). This has caused much resistance
to the use of whole-food animal-feeding studies because the
breadth of endpoints measured in the standard chemistry-based
90-day rat study and its lack of modiﬁcation to address the limited
number of endpoints known to reﬂect adverse effects with foods or
proteins. As such, many endpoints are measured without any
known example of a food or protein that can adversely affect these
endpoints. The typical endpoints measured in a 42-day broiler
study are more appropriate for evaluating food safety in that per-
formance parameters (general health, weight gain, feed consump-
tion, feed conversion, carcass measurements, etc.) are measured
rather than toxicological endpoints (which is more consistent with
evaluating foods and diets) (Herman et al., 2011a,b). However, a
formal survey of relevant adverse endpoints that might be caused
by foods or proteins is needed to better determine those endpoints
that might be useful to measure in animal-feeding studies aimed at
assessing the safety of whole foods. In addition, clear and reason-
able hypotheses should be articulated so that meaningful studies
can be designed rather than conducting exploratory studies devoid
of speciﬁc hypotheses. Finally, animal welfare should be consid-
ered in conducting any animal study. It is not consistent with ani-
mal welfare ethics to conduct studies that are unlikely to yield
meaningful results relevant to safety.5. Summary
It is important to clearly articulate the hypotheses that are
being tested in any animal study so that animals are not needlessly
sacriﬁced. A general search for unexpected adverse compositional
changes due to transgenesis is not warranted based on a survey
of the considerable empirical data that are available, or our under-
standing of the mechanisms that cause such changes (Herman and
Price, 2013). For expected compositional changes, exposure to the
changed constituents should be estimated and documented before
whole-food animal-feeding studies are considered. In addition,
other factors and knowledge should be examined and reasonable
doubt should be present regarding the safety of the compositional
change or component (Delaney et al., 2008). Efforts should also
ﬁrst be made to isolate the active components in question for
inclusion in controlled-dose animal diets before whole foods are
considered for use in such studies. Finally, when whole-food ani-
mal-feeding studies are deemed beneﬁcial for evaluating the safety
of a speciﬁc GM-crop, reasonable hypotheses should drive their de-
sign and the types of data collected.
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